3-hydroxybutyric acid has been researched along with Elevated Cholesterol in 5 studies
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In order to study the effect of HMG-CoA reductase inhibitor (pravastatin) on ketone formation, changes in the plasma levels of ketone bodies by treatment with pravastatin were studied in 18 non-insulin dependent diabetics with hypercholesterolemia." | 7.70 | Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia. ( Chiba, T; Fukuda, M; Nagakubo, H; Ogawa, S; Oouchi, M; Sato, C; Sato, T; Sugimura, K, 1998) |
| " In order to study the effect of HMG-CoA reductase inhibitor (pravastatin) on ketone formation, changes in the plasma levels of ketone bodies by treatment with pravastatin were studied in 18 non-insulin dependent diabetics with hypercholesterolemia." | 3.70 | Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia. ( Chiba, T; Fukuda, M; Nagakubo, H; Ogawa, S; Oouchi, M; Sato, C; Sato, T; Sugimura, K, 1998) |
| "Unified Parkinson's Disease Rating Scale scores improved in all five during hyperketonemia, but a placebo effect was not ruled out." | 2.71 | Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. ( Boyar, K; Di Rocco, A; Heymsfield, SB; Hyams, K; Nonas, C; Vanitallie, TB, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Song, T | 1 |
| Wang, P | 1 |
| Li, C | 1 |
| Jia, L | 1 |
| Liang, Q | 1 |
| Cao, Y | 1 |
| Dong, P | 1 |
| Shi, H | 1 |
| Jiang, M | 1 |
| Vanitallie, TB | 1 |
| Nonas, C | 1 |
| Di Rocco, A | 1 |
| Boyar, K | 1 |
| Hyams, K | 1 |
| Heymsfield, SB | 1 |
| Otero, P | 1 |
| Bonet, B | 1 |
| Herrera, E | 1 |
| Rabano, A | 1 |
| Bell, FP | 1 |
| DeLucia, AJ | 1 |
| Sato, T | 1 |
| Oouchi, M | 1 |
| Nagakubo, H | 1 |
| Chiba, T | 1 |
| Ogawa, S | 1 |
| Sato, C | 1 |
| Sugimura, K | 1 |
| Fukuda, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ketogenic Diet Interventions in Parkinson's Disease: Safeguarding the Gut Microbiome[NCT05469997] | 50 participants (Anticipated) | Interventional | 2023-01-31 | Not yet recruiting | |||
| Effect of a Lipidic and Proteic Controlled Diet on Resting Energy Expenditure, Body Composition and Symptoms in Patients With Parkinson's Disease[NCT02687698] | 36 participants (Anticipated) | Interventional | 2016-02-29 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for 3-hydroxybutyric acid and Elevated Cholesterol
| Article | Year |
|---|---|
Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Antiparkinson Agents; Cholesterol; Combined Modality The | 2005 |
Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Antiparkinson Agents; Cholesterol; Combined Modality The | 2005 |
Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Antiparkinson Agents; Cholesterol; Combined Modality The | 2005 |
Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Antiparkinson Agents; Cholesterol; Combined Modality The | 2005 |
4 other studies available for 3-hydroxybutyric acid and Elevated Cholesterol
| Article | Year |
|---|---|
Salidroside simultaneously reduces de novo lipogenesis and cholesterol biosynthesis to attenuate atherosclerosis in mice.
Topics: 3-Hydroxybutyric Acid; Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Diet, High-F | 2021 |
Development of atherosclerosis in the diabetic BALB/c mice. Prevention with Vitamin E administration.
Topics: 3-Hydroxybutyric Acid; Animals; Antioxidants; Arteries; Atherosclerosis; Blood Glucose; Body Weight; | 2005 |
Plasma and liver carnitine (free and esterified) levels and their interrelationships in moderately hypercholesterolemic monkeys (Macaca arctoides).
Topics: 3-Hydroxybutyric Acid; Acetylcarnitine; Animals; Carnitine; Hydroxybutyrates; Hypercholesterolemia; | 1983 |
Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Aged, 80 and over; Body Mass Index; Cholesterol; Diabete | 1998 |